, Volume 44, Issue 1, pp 65–71 | Cite as

Topical Corticosteroids

Which Drug and When?
  • Benvenuto Giannotti
  • Nicola Pimpinelli
Practical Therapeutics


A number of factors have to be taken into account when dealing with the treatment of skin diseases with topical corticosteroids, including disease type and phase, potency of the drug, safety, site to be treated, age of the patient, and drug formulation.

Concerning the specific indications for topical corticosteroid treatment, we can distinguish skin diseases in which: (a) topical corticosteroids are the treatment of choice; (b) topical corticosteroids are useful as alternative and/or adjuvant treatment; (c) the proposed use of topical corticosteroids has to be confirmed as useful; and (d) topical corticosteroids can be used as a symptomatic treatment. Within these groups, the treatment schedule has to be adjusted according to the abovementioned general factors.


Atopic Dermatitis Topical Corticosteroid Triamcinolone Acetonide Bullous Pemphigoid Beclomethasone Dipropionate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. August PJ. The choice of topical steroids — A personal view. Acta Dermato-Venereologica 69(Suppl. 151): 31–36, 1989Google Scholar
  2. Callen JP. Treatment of cutaneous lesions in patients with lupus erythematosus. Dematologic Clinics 8: 355–365, 1990Google Scholar
  3. Cullen SI. Effective topical dermatologie therapy. Dermatologic Clinics 7: 37–42, 1989PubMedGoogle Scholar
  4. Dalziel K, Millard P, Woinarowska FT. Lichen sclerosus et atro-phicus treated with a potent topical steroid (clobetasol dipro-pionate 0.05%). British Journal of Dermatology 121(Suppl. 34): 34–35, 1989CrossRefGoogle Scholar
  5. David M, Lowe NJ. Psoriasis therapy: comparative studies with hydrocolloid dressing, plastic film occlusion, and triamcino-lone acetonide cream. Journal of the American Academy of Dermatology 21: 511–514, 1989PubMedCrossRefGoogle Scholar
  6. du Vivier A. Tachyphylaxis to topically applied steroids. Archives of Dermatology 112: 1245–1248, 1976PubMedCrossRefGoogle Scholar
  7. Giannotti B. Current treatment guidelines for topical corticoste-roids. Drugs 36(Suppl. 5): 9–14, 1988PubMedCrossRefGoogle Scholar
  8. Guzzo C, Lavker RM, Roberts LJ, Fox K, Schechter N, et al. Urticaria pigmentosa: systemic evaluation and successful treatment with topical steroids. Archives of Dermatology 127: 191–196, 1991PubMedCrossRefGoogle Scholar
  9. Harper J. Topical corticosteroids for skin disorders in infants and children. Drugs 36(Suppl. 5): 34–37, 1988PubMedCrossRefGoogle Scholar
  10. Hoppe G. Diflucortolone valerate: Asian experience. Drugs 36(Suppl. 5): 24–33, 1988PubMedCrossRefGoogle Scholar
  11. Hradil E, Lindstrom C, Moller H. Intermittent treatment of psoriasis with clobetasol propionate. Acta Dermato-Venereologica 58: 375–377, 1978PubMedGoogle Scholar
  12. Juhlin L. Treatment of psoriasis and other dermatoses with a single application of a corticosteroid left under a hydrocolloid occlusive dressing for one week. Acta Dermato-Venereologica 69: 355–357, 1989PubMedGoogle Scholar
  13. Katsambas A, Antoniou G, Frangouli E, Augerinou G, Michailidis D, et al. A double-blind trial ot treatment of seborrheic dermatitis with 2% ketoconazole cream compared with 1% hy-drocortisone cream. British Journal of Dermatology 121: 353–357, 1989PubMedCrossRefGoogle Scholar
  14. Katz HI, Hien NT, Prawer SE, Mastbaum LI, Mooney JJ, et al. Superpotent topical steroid treatment of psoriasis vulgaris: clinical efficacy and adrenal function. Journal of the American Academy of Dermatology 16: 804–811, 1987aPubMedCrossRefGoogle Scholar
  15. Katz HI, Hien NT, Prawer SE, Scott JC, Grivna EM. Betame-thasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Archives of Dermatology 123: 1308–1311, 1987bPubMedCrossRefGoogle Scholar
  16. Katz HI, Prawer SE, Watson MJ, Scull TA, Peets EA. Mometa-sone furoate ointment 0.1% vs hydrocortisone ointment 1.0% in psoriasis: atrophogenic potential. International Journal of Dermatology 28: 342–344, 1989PubMedCrossRefGoogle Scholar
  17. Lavker RM, Schechter NM, Guzzo C, Lazarus GS. Aggressive topical corticosteroid therapy: a novel approach to mast cell-dependent cutaneous disorders. Dermatologica 175: 213–216, 1987PubMedCrossRefGoogle Scholar
  18. Liu XG, Shao CG, Jin PY, Wang HQ, Ye GY, et al. Treatment of localized vitiligo with ulobetasol cream. International Journal of Dermatology 29: 295–297, 1990PubMedCrossRefGoogle Scholar
  19. Lubach D, Bensmann A, Bornemann U. Steroid-induced dermal atrophy: investigation on discontinuous application. Dermatologica 179: 67–72, 1989PubMedCrossRefGoogle Scholar
  20. Miller JA, Munro DD. Topical corticosteroids: clinical pharmacology and therapeutic use. Drugs 19: 119–134, 1980PubMedCrossRefGoogle Scholar
  21. Noren P, Melin L. The effect of combined topical steroids and habit-reversal treatment in patients with atopic dermatitis. British Journal of Dermatology 121: 359–366, 1989PubMedCrossRefGoogle Scholar
  22. Ortonne JP. Clinical potential of topical corticosteroids. Drugs 36(Suppl. 5): 38–42, 1988PubMedCrossRefGoogle Scholar
  23. Pierard GE, Pierard-Franchimont C, Ben Mosbah T, Arrese Estrada J. Adverse effects of topical corticosteroids. Acta Dermato-Venereologica 69(Suppl. 151): 26–30, 1989Google Scholar
  24. Polano MK. Corticosteroids for topical use in topical skin therapeutics. Churchill Livingstone, New York, 1984Google Scholar
  25. Reynolds NJ, Peachey RD. Response of atypical bullous pyod-erma gangrenosum to oral minocycline hydrochloride and topical steroids. Acta Dermato-Venereologica 70: 538–539, 1990PubMedGoogle Scholar
  26. Takeda K, Arase S, Takahashi S. Side effects of topical corticosteroids and their prevention. Drugs 36(Suppl. 5): 15–23, 1988PubMedCrossRefGoogle Scholar
  27. Thiers BH. Topical steroid therapy of atopic skin diseases. Allergy Proceedings 10: 413–416, 1989PubMedCrossRefGoogle Scholar
  28. Topert M. Perspectives in corticosteroid research. Drugs 36(Suppl. 5): 1–8, 1988PubMedCrossRefGoogle Scholar
  29. Trozac DJ. Topical corticosteroid therapy in psoriasis. Cutis 46: 341–350, 1990Google Scholar
  30. Turpeinen M. Absorption of hydrocortisone from the skin reservoir in atopic dermatitis. British Journal of Dermatology 124: 358–360, 1991PubMedCrossRefGoogle Scholar
  31. Uppal R, Sharma SC, Bhowmik SR, Sharma PL, Kaur S. Topical corticosteroid usage in dermatology. International Journal of Pharmacologic Therapy and Toxicology 29: 48–50, 1991Google Scholar
  32. Van der Harst LCA, de Jonge H, Pot F, Polano MK. Comparison of two application schedules for clobetasol-17-propionate. Acta Dermato-Venereologica 62: 270–273, 1982Google Scholar
  33. Van der Valk PG, Maibach HI. Do topical corticosteroids modulate skin irritation in human beings? Assessment by transe-pidermal water loss and visual scoring. Journal of the American Academy of Dermatology 21: 519–522, 1989PubMedCrossRefGoogle Scholar
  34. Verbov J. The place of intralesional steroid therapy in dermatology. British Journal of Dermatology 94(Suppl. 12): 51–58, 1976PubMedCrossRefGoogle Scholar
  35. Vilgioglia P, Jones ML, Peets FA. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate in the treatment of a variety of dermatoses. Journal of International Medical Research 18: 460–467, 1990Google Scholar
  36. Watson WA, Kalb RE, Siskin SB, Frer JP, Krochmal L. The safety of halobetasol 0.05% ointment in the treatment of psoriasis. Pharmacotherapy 10: 107–111, 1990PubMedGoogle Scholar
  37. Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. Journal of the American Academy of Dermatology 20: 458–461, 1989PubMedCrossRefGoogle Scholar
  38. Wilkinson SM, Cartwright PH, English JS. Hydrocortisone: an important cutaneous allergen. Lancet 337: 761–762, 1991PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Benvenuto Giannotti
    • 1
  • Nicola Pimpinelli
    • 1
  1. 1.Clinica Dermosifilopatica IIUnivesità Degli Studi di FirenzeFirenzeItaly

Personalised recommendations